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Abstract 25 
Primary aldosteronism is a common cause of endocrine hypertension. It results from the excess production 26 
of aldosterone by the adrenal cortex and is related to increased morbidity and mortality. Most cases of PA 27 
are sporadic but inherited patterns of the disease have been reported in the literature. Four forms of 28 
familial hyperaldosteronism (FH-I- FH-IV) are currently recognized, and the genetic basis has been 29 
clarified in recent years. In FH-I patients, aldosterone excess is produced by a CYP11B1/CYP11B2 fusion 30 
gene and it is suppressed by glucocorticoid treatment. FH-II is caused by mutations in the inwardly 31 
rectifying chloride channel CLCN2. FH-III is caused by mutations in KCNJ5, a gene coding for an inward 32 
rectifier K+ channel and mutations in the T-type calcium channel subunit CACNA1H cause FH-IV. In this 33 
review we summarize the knowledge on inherited forms of primary aldosteronism, the genetic alterations 34 
that cause them and the implications it may have for the classification. Based on current evidence, we 35 
propose the term “familial hyperaldosteronism” to refer only to inherited forms of primary aldosteronism 36 
with a known genetic basis. 37 
 38 
 39 
Primary aldosteronism (PA) is the clinical manifestation of a heterogeneous group of adrenal disorders 40 
that are characterized by an excessive production of aldosterone, which becomes relatively independent of 41 
the angiotensin-renin system regulation. Over time, sustained levels of aldosterone lead to increased blood 42 
pressure and elevated potassium excretion, therefore patients with PA are hypertensive, in many cases 43 
hypokalemic, and at higher risk of stroke, renal complications, metabolic and cardiovascular mortality 44 
than patients with essential hypertension. Once classified as a rare disease, PA is now considered the most 45 
common cause of endocrine hypertension, with an estimated prevalence of about 4-6% in the general 46 
population with hypertension and up to 10-20% in the subset of patients with resistant hypertension [1–3]. 47 
Most diagnosed cases of PA are sporadic and are mainly caused by aldosterone overproduction by both 48 
adrenal glands (bilateral adrenal hyperplasia) or by unilateral aldosterone-producing adenomas (APA). 49 
Other causes include unilateral hyperplasia and very rarely, adrenocortical carcinomas. In some cases, PA 50 
affects several members of the same family in the inherited or familial forms of hyperaldosteronism (FH). 51 
Current guidelines recognize three well established types of FH, namely FH-I to FH-III [4], however data 52 
from genetic analyses reveal a more complex situation, with at least 4 different inheritable forms of PA 53 
and possibly still more yet to be discovered. 54 
 55 
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Genes associated with inherited forms of PA 56 
The genetics of PA has remained obscure for a long time. Although infrequent, the early onset and the 57 
heritability favored the study of familial PA as an approach to understand the pathophysiology of the more 58 
common sporadic forms. The identification of the first genetic alteration causative for a particular subtype 59 
of PA by linkage analysis on affected relatives, the chimera CYP11B1/CYP11B2 [5],  was an outstanding 60 
discovery but subsequent investigation quickly revealed that it was not present in sporadic forms [6,7]. 61 
The failure to find new causative genes and the introduction of next generation sequencing techniques 62 
turned the focus to sporadic patients.  63 
Now that hundreds of APAs have been sequenced, it is well known that KCNJ5, CACNA1D, ATP1A1 and 64 
ATP2B3 genes are mutated in about 50% of adenomas (reviewed in [8] and [9]) and that ion channels and 65 
pumps exert an important role on aldosterone signaling through the control of Ca2+ influx [10]. Following 66 
the trend of next generation sequencing of sporadic cases, the study of patients with early-onset PA has 67 
uncovered that some of those genes also exert an important role in inherited forms. Thus, KCNJ5 germline 68 
mutations cause FH-III and CACNA1H mutations have been found in families with FH-IV and de novo 69 
germline mutations in CACNA1D have been reported in patients with early onset of PA, seizures and 70 
neurologic abnormalities (PASNA). In addition, two recent studies in patients with early-onset PA have 71 
shown mutations in CLCN2 associated with FH-II. Table 1 summarizes the genes associated with PA and 72 
the main clinical features and Figure 1 depicts the molecular mechanisms.  73 
 74 
CYP11B1/CYP11B2 chimera: Familial Hyperaldosteronism Type I (FH-I) 75 
FH-1 was first reported in 1966 by Sutherland and colleagues [11].  They reported two hypertensive 76 
relatives, a father and a son, with a condition that mimicked the symptoms of sporadic PA (increased 77 
aldosterone, low renin activity and hypokalemia) but with the particularity of suppression of aldosterone 78 
production by a 2 mg/day dexamethasone treatment. Thus FH-I is often referred to as glucocorticoid-79 
remediable aldosteronism (GRA). The basis of the glucocorticoid suppression was discovered in 1992, 80 
after linkage analysis identified the genetic cause as a chimeric fusion on chromosome 8 containing an 81 
unequal recombination between the highly homologous genes CYP11B1 (11-β-hydroxylase) and 82 
CYP11B2 (aldosterone synthase) [5]. The exact point of cross-over can be different in each reported 83 
family but always contains the promoter and the first exons of CYP11B1 and most of the coding region of 84 
CYP11B2, resulting in an enzyme with aldosterone synthase activity with expression under the control of 85 
the adrenocorticotropic hormone (ACTH) instead of angiotensin II and potassium. As a consequence, 86 
aldosterone synthase is expressed in the zona fasciculata rather than in the zona glomerulosa, resulting in 87 
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the ectopic production of aldosterone and the production of the hybrid steroids 18-oxocortisol and 18-88 
hydroxycortisol [5,12].  89 
FH-I is considered as a rare subgroup of PA that represents less than 1% of all cases, increasing to 3% in 90 
children with hypertension [13–15]. It is characterized by the development of bilateral adrenal 91 
hyperplasia, occasionally adrenal nodules, with variable clinical and biochemical features [14,16]. FH-I 92 
follows an autosomal dominant inheritance pattern and is generally associated with early onset severe 93 
hypertension and an increased risk of stroke; however, different degrees of severity have been reported, 94 
including cases of mild hypertension and normotensive individuals [16–18].  95 
The Endocrine Society guideline recommends testing for FH-I in patients with an early onset of PA (<20 96 
years old) and in those with a familial occurrence of PA or stroke at a young age (<40 years old) [4]. The 97 
correct diagnosis is clinically relevant because aldosterone excess can be controlled successfully through 98 
glucocorticoid therapy [19]. Prior to the existence of targeted molecular tests, the diagnosis was made 99 
through clinical and biochemical evaluation. Dexamethasone suppression of aldosterone and levels of 100 
hybrid steroids were used to establish a diagnosis of FH-I [20,21] until the introduction of techniques to 101 
specifically detect the presence of the CYP11B1/CYP11B2 chimeric gene either by Southern blotting or by 102 
the recommended technique employing a long-chain PCR amplification [4, 21,22].  103 
In patients with FH-I aldosterone production is abrogated under glucocorticoid treatment, and partial 104 
suppression of ACTH is enough to correct the hypertension associated with FH-I. Accordingly, low doses 105 
of dexamethasone are recommended to achieve normotension whilst preventing undesired cushingoid 106 
features [19]. Mineralocorticoid receptor antagonists (spironolactone or eplerenone) can be used as a 107 
second line of therapy to block possible non-genomic effects of aldosterone on target organs, or in 108 
children to avoid possible side effects of dexamethasone treatment [24].  109 
 110 
CLCN2: Familial Hyperaldosteronism Type II (FH-II) 111 
FH-II was first described by Gordon et al. in 1991, a year before the genetic cause of FH-I was published. 112 
They described 6 relatives from 3 independent affected families who presented with PA caused by either 113 
APA or BAH and a lack of suppression of aldosterone production by fludrocortisone or 114 
dexamethasone[25]. Several families were reported by the same group shortly thereafter [26,27].  115 
Until very recently, the genetic cause of FH-II remained elusive. Early targeted genetic studies showed a 116 
lack of mutations on genes related to steroidogenic production or tumorigenesis, such as CYP11B2, the 117 
angiotensin receptor AT1R or TP53. Later on, genetic linkage analysis of non-related families highlighted 118 
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a locus at chromosome 7p22 that segregates with the disease in some families, but not in all cohorts [28–119 
30]. However both targeted sequencing of different genes in that region as well as next-generation 120 
sequencing of the complete locus have failed to find mutations [29,31–33]. Scholl and colleagues 121 
analyzed the genomic DNA by exome sequencing of three members from one of the FH-II families 122 
described by Stowasser et al. in 1992 [27]. The authors identified a germline mutation in the gene CLCN2 123 
that segregated with the disease. This variant, p.Arg172Gln, was confirmed subsequently in five additional 124 
family members, four of them with aldosterone-to-renin ratio suggestive of PA [34]. Because the 125 
discovery family was one of the first families diagnosed with FH-II, Scholl et al. proposed the use of that 126 
term only for inherited PA due to CLCN2 mutations [34]. The authors also reported the same mutation in 127 
three additional unrelated individuals, as well as rare germline CLCN2 variants (p.Met22Lys, p.Tyr26Asn, 128 
p.Lys362del and Ser865Arg, with allele frequencies below 10−5) in four additional unrelated patients [34]. 129 
Simultaneously, Fernandes-Rosa and colleagues identified another germline CLCN2 mutation in a 9-130 
years-old patient by exome-sequencing sequencing of genomic DNA from 12 patients with young-onset 131 
hypertension and PA. In that case, p.Gly24Asp was a de novo mutation. Two additional variants were 132 
found in two cases from a cohort of 100 patients with idiopathic bilateral adrenal hyperplasia (p.Arg66Gln 133 
and p.Pro48Arg, with minor allele frequencies of 3x10-5 and 1.7 x 10-4, respectively) [35]. Both studies 134 
showed that CLCN2 mutations were related to PA diagnosed at early age and absent in patients with 135 
essential hypertension [34,35].  136 
CLCN2 gene is located in chromosome 3q27 and encodes the inwardly rectifying chloride channel ClC2, a 137 
member of the CLC voltage-gated Cl- channels family. ClC2 is broadly expressed in mammalian cells, 138 
especially in brain, gut, kidney, heart and liver [36]. Mutations inactivating CLCN2 cause leukodystrophy, 139 
in some cases with azoospermia, and Clcn2 knockout mice also develop early postnatal retinal 140 
degeneration [37–39]. Scholl et al. and Fernandes-Rosa et al. have shown that ClC2 is also expressed in 141 
the adrenal gland. Furthermore, germline mutations that associate with PA result in gain of function of the 142 
Cl- channel, causing an efflux of Cl- ions that leads to the depolarization of the plasma membrane, the 143 
consequent opening of voltage-gated Ca2+ channels, the accumulation of cytosolic Ca2+ and the activation 144 
of CYP11B2 transcription [34,35].  145 
Before the recent discovery of CLCN2 mutations, screening for FH-II was based on the diagnosis of PA in 146 
at least two first-degree members of the same family and the absence of known germline mutations. Thus, 147 
this familial form was thought to be the most prevalent, representing about 3-6% of all PA cases [11,54]. 148 
Nevertheless, Korah and Scholl pointed out that this estimation may be misleading: considering the 149 
prevalence of hypertension in the general population (about 30%) and the PA prevalence in the general 150 
population with hypertension (about 5%), the probability for an index case to have at least a first-degree 151 
relative with PA just by chance is ~5.9% [40]. Accordingly, it is likely that some of the described FH-II 152 
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families were in fact coincidental cases of sporadic idiopathic PA. This observation may explain, at least 153 
partially, the apparent heterogeneity reported in previous studies. To avoid confusion, and to base the 154 
classification on a simple and transparent genetic basis, similar to other genetic diseases, we propose to 155 
use the term “familial hyperaldosteronism” only when an inherited genetic cause is established.  156 
Following this reasoning, the number of true FH-II families is probably much lower than previously 157 
reported. In their studies, Scholl et al. and Fernandes-Rosa et al. identified CLCN2 mutations in about 158 
10% of cases with young-onset PA without known germline mutations and 2% with bilateral adrenal 159 
hyperplasia [34,35] suggesting a lower frequency than previous estimates. Further efforts are needed to 160 
determine the actual prevalence of FH-II. 161 
  162 
KCNJ5: Familial Hyperaldosteronism Type III (FH-III) 163 
FH-III was described by Geller et al. in three family members, a father and his two young daughters, who 164 
developed hyperaldosteronism with hypokalemia and severe hypertension at very early age, together with 165 
marked bilateral adrenal enlargement. High levels of the hybrid steroids 18-oxocortisol and 18-166 
hydroxycortisol were detected in urine samples but the disorder was distinguishable from FH-I by the 167 
glucocorticoid resistance of the hyperaldosteronism and the lack of suppression of aldosterone production 168 
on dexamethasone suppression testing. Hypertension and hypokalemia were refractory to medical therapy 169 
and disease control was achieved only after bilateral adrenalectomy [41]. Careful examination of the 170 
adrenals revealed disorganized zonation, a reduction in the thickness of the zona glomerulosa, an enlarged 171 
zona fasciculata and the presence of cells that co-express enzymes which are usually expressed in distinct 172 
zones, such as CYP11B1 and CYP11B2 and also CYP17 and CYP11B2. The co-expression of CYP17 and 173 
CYP11B2 is the likely basis for the production of hybrid steroids [12,41,42].  174 
It was not until 2011 that the genetic etiology of FH-III was clarified. By means of exome sequencing, 175 
Choi et al. identified a heterozygous germline mutation located on chromosome 11q24 in the patients 176 
reported by Geller and colleagues, as well as in sporadic cases of PA [43]. The affected gene was KCNJ5, 177 
which codes for the G-protein-activated inward rectifier K+ channel 4 (Kir3.4). This protein forms homo- 178 
and heterotetramers with other Kir family members to constitute the functional G-protein-activated 179 
inwardly rectifying potassium channel, which contributes to the control of membrane polarity in the zona 180 
glomerulosa [44]. The mutation identified in Geller’s cases (p.Thr158Ala) was associated with a loss in 181 
K+ selectivity and an increased influx of Na+ into the cytoplasm, leading to membrane depolarization and 182 
the elevation of intracellular Ca2+ levels, which ultimately triggers aldosterone production through the 183 
activation of Ca2+-related signaling pathways [45].  184 
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Since the link between inherited PA and KCNJ5, several familial cases with different mutations in that 185 
gene have been published, mostly in or next to the selectivity filter [46–51], and the term FH-III is used 186 
for familial cases with PA due to germline KCNJ5 mutations, regardless of the phenotype. Indeed, the 187 
clinical features of the affected cases vary all along the PA spectrum, from mild and treatment-responding 188 
forms to severe PA with progressive disease, including symptoms mimicking diabetes insipidus and a 189 
recent report showing development of Cushing´s syndrome in one patient with FH-III [50]. This 190 
variability seems to be dependent on the type of the grounding KCNJ5 mutations, among other 191 
factors[46]. Thus, p.Gly151Glu mutations seem to associate with a milder phenotype and stable disease 192 
[46,49], while  p.Gly151Arg, p.Thr158Ala, p.Ile157Ser and p.Tyr152Cys mutations relate to a more 193 
severe hyperaldosteronism [52]. Other infrequent germline alterations of KCNJ5 (some of them de novo) 194 
and a rare non-synonymous SNP (rs7102584) have been described. The mutation p.Glu145Gln affects a 195 
salt bridge close to the selectivity filter, while mutations p.Arg52His, p.Glu246Lys, p.Gly247Arg and the 196 
SNP Glu282Gln were located elsewhere in the protein [53,54]. Except of the p.Gly247Arg, those variants 197 
altered channel functionality and increased aldosterone production compared with the wild-type protein. 198 
The prevalence of FH-III has not been established systematically but it is estimated to be present in <1% 199 
of all PA cases [47]. The Endocrine Society guideline recommends testing for FH-III by sequencing 200 
peripheral blood for mutations in KCNJ5 in those patients with a very early onset of PA [4]. Because of 201 
the variety of presentations, treatment for FH-III depends on the severity of the disease. Milder cases can 202 
be well controlled with spironolactone, while adrenalectomy is currently the best option to treat resistant 203 
forms successfully [52]. 204 
 205 
CACNA1H: Familial Hyperaldosteronism Type IV (FH-IV) 206 
FH-IV was reported by Scholl and coworkers in a cohort of 40 patients diagnosed with PA in early 207 
childhood (at age 10 years or below) and without mutations in any common known PA genes. By whole 208 
exome sequencing analysis, a recurrent mutation in the gene CACNA1H was identified in five unrelated 209 
patients, four males and one female [55]. Shortly thereafter Daniil et al. reported the presence of different 210 
mutations in the same gene in two unrelated individuals who were diagnosed originally with FH-II, as 211 
well as an adult male case with a de novo mutation and an adult female patient with an APA and a 212 
germline mutation in the same gene [56]. Patients showed no apparent signs of seizures, cardiac 213 
arrhythmia or muscular or neurological alterations that have been commonly linked to other disorders 214 
caused by CACNA1H germline mutations or by another Ca2+ channel subunit, CACNA1D [57], although 215 
one of the patients was diagnosed with minor mental retardation and multiplex developmental disorder 216 
[56]. So far, eight families with FH-IV have been described. 217 
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The gene CACNA1H is located on chromosome 16 and encodes the T-type (low voltage activated) 218 
calcium channel subunit Cav3.2. This protein is expressed in the zona glomerulosa [55,57] and, as other 219 
Cav3 family members, is activated by small depolarizing changes in the membrane potential [58]. 220 
Germline CACNA1H mutations have been associated with several diseases including epilepsy, autism and 221 
amyotrophic lateral sclerosis [59–61]. In their studies, Scholl et al. and Daniil et al. reported six index 222 
cases with germline mutations affecting the residue Met1549, four cases with an inherited p.Met1549Val 223 
substitution, one with a de novo p.Met1549Val and one with a de novo p.Met1549Ile [55,56]. This residue 224 
is located in the transmembrane segment S6 of the repeat domain III of Cav3.2, forming a conserved 225 
methionine-phenylalanine-valine (MFV) tripeptide motif that controls channel inactivation [62]. 226 
Functional experiments have demonstrated that mutations in Met1549 result in a decrease in the 227 
inactivation of Cav3.2 compared with the wild-type protein. As a consequence, the channel remains open 228 
longer with an increase in Ca2+ influx, which activates the expression of CYP11B2 and other steroidogenic 229 
genes [55,56,63]. Noteworthy, treatment with a T-type calcium channel blocker abrogated the aberrant 230 
CYP11B2 activation and aldosterone production in HAC15 cells overexpressing Cav3.2 p.Met1549Val 231 
mutant channels, which indicates that drugs of this class could be useful in the treatment of patients with 232 
FH-IV [63].  233 
In their study, Daniil et al. reported 3 additional variants: p.Ser196Leu, located in the voltage sensor 234 
region on the transmembrane segment S4 of the repeat domain I of Cav3.2, in a male patient and his sister; 235 
p.Pro2083Leu, located in the C-terminal cytoplasmic domain, in another index case and his brother; and a 236 
de novo p.Val1951Glu, also located in the C-terminal domain, in a patient with an APA (no familial 237 
history available). All mutations altered Cav3.2 function and enhanced aldosterone production to a greater 238 
or a lesser degree [56].  239 
Although further studies are needed, available data suggests FH-IV may be a rare form of FH. It follows 240 
an autosomal dominant pattern of heritability but with reduced penetrance, particularly in adults. Indeed, 241 
some family members with mutations in p.Met1549 were affected with resistant hypertension and PA and 242 
others displayed milder or even normotensive phenotype, suggesting that other factors, such as genetic 243 
modifiers, somatic mosaicism or the age of the patient, could restrain the gene defect [55]. The type and 244 
location of the mutation may also play a role in the pathophysiology of FH-IV, resembling what has been 245 
described for KCNJ5 [46]. This fact could also explain the differences on disease presentation among the 246 
index cases: some of them were florid cases of PA at their early childhood but without evidence of adrenal 247 
hyperplasia; while other patients were diagnosed in their adulthood, nodularity was detected bilaterally in 248 
one patient and an APA was diagnosed in another case [55,56].  249 
 250 
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Other germline mutations described in patients with PA  251 
Although not considered established causes of FH, it is worth mentioning that germline mutations in 252 
CACNA1D and ARMC5 have been reported in patients with PA.  253 
CACNA1D codes for Cav1.3, an L-type (high-voltage activated) Ca2+ channel subunit and is recurrently 254 
mutated in about 10% of sporadic APAs. Most sporadic alterations cause gain of function and lead to an 255 
increase of Ca2+ influx and the consequent overproduction of aldosterone [57]. Recently, Scholl and 256 
coworkers identified two de novo mutations in two unrelated cases diagnosed with PASNA (PA 257 
associated with seizures and neurological abnormalities) [57]. Although the severe comorbidities of 258 
affected individuals make the heritability of PASNA very unlikely, it is tempting to speculate that other 259 
CACNA1D mutations that cause a milder phenotype could be involved in a still not described familial 260 
form of PA, in the same way that has been proposed for KCNJ5 in FH-III. 261 
ARMC5 encodes an apoptosis regulator that belongs to the armadillo/β-catenin-like repeat superfamily. 262 
Inactivating mutations in ARMC5 have been reported in both sporadic and inherited primary bilateral 263 
macronodular hyperplasia, an adrenocortical disease associated with cortisol excess [64–66]. Mutated 264 
ARMC5 promotes cell survival and cortisol production in vitro [64,65]. Interestingly, germline ARMC5 265 
variants have been identified in patients with apparent sporadic cases of PA [67,68], suggesting a possible 266 
inherited predisposition for nodule formation prior to the hormonal-producing phenotype. Nevertheless, 267 
the deleterious effect of those mutations is still quite unclear, as most variants are predicted to be unlikely 268 
pathogenic [69]. Thus, further studies must confirm or refuse the possible role of ARMC5 germline 269 
mutations in the etiology of PA.  270 
 271 
New genes, new phenotypes - We need a new classification! 272 
In the recent years, our knowledge on inherited forms of PA has progressed substantially [8,70]. FH 273 
classification has evolved from two clinically distinct forms (FH-I and FH-II) described in the previous 274 
Endocrine Society guideline [71] to at least four genetically defined types in which patients are grouped 275 
based on the presence of causative mutations (FH-I/CYP11B1/B2 chimera, FH-II/CLCN2, FH-III/KCNJ5 276 
and FH-IV/CACNA1H). Despite substantial scientific advances, some questions remain unanswered. 277 
Firstly, the clinical heterogeneity within groups of FH related to variable disease presentation and 278 
incomplete penetrance suggest a possible modulation of genetic causes by non-genetic factors. This 279 
hypothesis could explain why relatives with germline mutations are apparently asymptomatic. Secondly, 280 
the prevalence of FH-II and FH-IV families is still uncertain. Evidence suggests that the frequency of 281 
CLCN2 and CACNA1H mutations is low. Thus, extensive studies are needed to determine the actual 282 
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prevalence and the clinical relevance of these subtypes. Lastly, it must be elucidated whether apparent 283 
familial cases without known mutations truly follow inherited patterns of PA. Further next-generation 284 
sequencing studies will gain insight into the molecular causes of PA and probably to contribute to the 285 
establishment of new FH types. Misclassification of sporadic PA cases as FH should be avoided. For that 286 
reason, we discourage the use of non-genetic criteria for the screening and classification of FH and 287 




This work was supported by the European Research Council (ERC) under the European Union’s Horizon 292 
2020 research and innovation programme (grant agreement No [694913] to MR) and by the Deutsche 293 
Forschungsgemeinschaft (DFG) (within the CRC/Transregio 205/1 “The Adrenal: Central Relay in Health 294 
and Disease” to MR and TAW; and grant RE 752/20-1 to MR) and the Else Kröner-Fresenius Stiftung in 295 
support of the German Conns Registry-Else-Kröner Hyperaldosteronism Registry (2013_A182 and 296 
2015_A171 to MR). L.G.P-R is supported by a fellowship from the People Programme (Marie Curie 297 
Actions) of the European Union’s Seventh Framework Programme (FP7/2007–2013) under REA grant 298 
agreement no. 608765.  299 
 300 
  301 
 11 
Figure 1. Genetic causes of familial hyperaldosteronism. Summary of the known molecular 302 
mechanisms that lead to familial hyperaldosteronism types I to IV. FH-I is produced by an asymmetrical 303 
recombination between CYP11B1 and CYP11B2, resulting in the expression of a chimeric enzyme under 304 
the control of ACTH stimulation. FH-II is caused by germline mutations in the chloride channel CLCN2 305 
that decrease intracellular Cl-. FH-III is produced by germline mutations in KCNJ5 that affect the 306 
selectivity of the channel, allowing Na+ conductance. Both reduction of intracellular Cl- and increase in 307 
Na+ cause plasma membrane depolarization and open voltage-gated Ca2+ channels, elevating cytosolic 308 
Ca2+. FH-IV is caused by germline mutations in CACNA1H that facilitate Ca2+ entry. In all cases, increase 309 
of intracellular Ca2+ triggers CYP11B2 transcription and aldosterone synthesis. 310 
 311 
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